Skip to content
DataLookout
Menu

NCT07374848

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words
    • Trial sites expanded: 8 → 12 locations
  2. Minor Study sites: 6 to 8v7
  3. Minor Study sites: 5 to 6v5
  4. Minor Trial sites expanded: 2 → 5 locations
    • Start date changed from estimate of Mar 2026 to Mar 2, 2026
    v4
  5. Minor Study sites: 1 to 2v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Dose Limiting Toxicities
Timeframe: 1 cycle of study treatment (each cycle is 21 days)
Incidence of Treatment Emergent Adverse Events
Timeframe: 36 months
Incidence of Serious adverse events
Timeframe: 36 months
Number of participants with clinical laboratory abnormalities
Timeframe: 36 months
Number of participants with vital sign abnormalities
Timeframe: 36 months
Number of participants with electrocardiogram (ECG) abnormalities
Timeframe: 36 months

Secondary (6)

ORR per RECIST 1.1
Duration of Response per RECIST 1.1
PFS per RECIST 1.1
DCR per RECIST 1.1
PK characteristics of ZL-6201 (ADC conjugate), total antibody
Show 1 moreShow less
PK characteristics of ZL-6201 (ADC conjugate), unconjugated payloads

Arms and interventions

ZL-6201Experimental

ZL-6201 as a single agent

Drugs: ZL-6201

Sites

12 sites in 2 countries

United States 7, China 5